Study of a valve treatment for severe leaking tricuspid valve
Part of Heart & circulation clinical trials.
This trial looks at a catheter-based procedure using the TricValve system for people with severe “tricuspid regurgitation” (a leaky tricuspid valve) who are very symptomatic. It may help reduce the backflow and improve heart function, especially for people who are too unwell for or not helped by standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your echocardiogram and right-heart measurements show severe tricuspid valve leaking with strong backflow pressure in the IVC and/or SVC
- CT scan shows your heart anatomy is suitable for the TricValve bicaval valve implant
- Your symptoms are severe (NYHA class III or IV) and you can walk at least 60 meters in a 6-minute walk test
- You can give consent (or your legal guardian can), and you can return for required follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device called TricValve, which is placed through a catheter (a thin tube) to fix a leaky tricuspid valve on the right side of the heart. It aims to reduce blood flowing backward and improve heart failure symptoms for people who can't have open-heart surgery and haven't been helped by other catheter treatments.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a new valve device for people with severe leakage of the tricuspid valve. The device is placed inside the heart without open surgery, with the goal of reducing the leak and improving symptoms like shortness of breath and swelling.
This study tests a new device to help people with severe tricuspid regurgitation (leaky heart valve) who are at higher risk from surgery. It aims to see if the device can reduce the leak and improve symptoms.
This trial tests a new, less-invasive device called 'Pivot Extend' for people with a severe leaky tricuspid valve (tricuspid regurgitation) who still have symptoms despite taking medicines. The goal is to see if the device can safely help reduce the leak and improve symptoms.
Hear when a new Severe Tricuspid Valve Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.